Alv B

07/06/2023

Lovely article from forskning.no detailing how our research has been brought to life in the clinic. Together with our veterinarian partners at NMBU, the article highlights the first two dogs who have undergone our innovative treatment protocol for lung metastasis, including Misty, an 11-year old Maltese/Shih tzu mix who travelled with her owner all the way from the Netherlands to receive treatment. The good news is that CT confirms partial remission and stabilisation of an otherwise aggressive disease. Read more in the article below (in Norwegian) about Misty's story and the work we’re doing in clinic to improve cancer care in dogs.

https://lnkd.in/d9JeAHJN

Mark Klaver har reist fra Nederland til Ås fem ganger for at hunden Misty (12) skal få en ny immunterapi mot kreft. Misty er med i et utprøvende forsøk ved Veterinærhøgskolen som kan forlenge hunders liv.

14/04/2023

Say hello to Joy, the first dog to undergo our innovative treatment protocol. Joy is an 11 year old cocker spaniel, who was sadly diagnosed with breast (mammary) cancer which spread to her lungs. Alv B, together with our dedicated veterinary partners at NMBU, are hopeful we can improve the length and quality of her life.

20/03/2023

Folkeinvest gratulerer Alv B med vellykket kapitalinnhenting på 9,3 MNOK.

Alv B utvikler kreftbehandling for hund, med direkte overføringsverdi til humanmedisin. Planlagt børsnotering i 2024.

Innhentet kapital skal finansiere videre kommersialisering i 2023.

31/01/2023

Like humans, dogs can also develop aggressive cancers in the head and neck, and can hugely decrease the quality of life for our beloved companions; impacting the dog’s ability to eat, smell or even see. At Alv B AS, we are committed to developing novel therapies for these hard-to-treat cancers. With our team of dedicated scientists and veterinarians, we are developing the next generation of immunotherapies to improve cancer care in dogs, ultimately giving them a better quality of life and allowing them to be a loved member of the family for longer.

Like humans, dogs can also develop aggressive cancers in the head and neck, and can hugely decrease the quality of life for our beloved companions; impacting…

25/01/2023

Alv B nevnes i et kjempeflott innslag fra veterinær Geir Erik Berge om fremskritt innenfor immunterapi, og bruken av hund som modell for human kreft. Innslaget går over to segmenter.

Så frø i snø Når snøen ligger som et teppe i hagen og blomsterkassene er bånnfryst, virker våren så veldig langt unna. Men det er fullt mulig å sysle litt i hagen selvom det er vinter. Man kan faktisk så selvom det er snø. Mauds gullkjole Dronning Maud hatet oppmerksomheten under kroninge...

10/01/2023

We’ve just became the #1 most followed startup on Folkeinvest! If you want to find out why people are so interested in Alv B, click the link below to register your interest and be notified when the campaign opens.

Revolusjonerende kreftbehandling for hund, med direkte overføringsverdi til humanmedisin. Meget gode resultater. Kommersialisering i 23, børs i 24

04/01/2023

(English: bottom of post)

Vi inviterer nysgjerrige, potensielle investorer og eksisterende aksjonærer til et uformelt informasjonsmøte om Alv B, 11 januar på Teams eller i Forskningsparken.

Påmelding via registreringsskjema: https://lnkd.in/ddTBCpxB

The presentation is mainly in Norwegian, but if you would like an English language presentation, please get in touch.

https://www.linkedin.com/posts/alv-b-as_english-bottom-of-post-vi-inviterer-nysgjerrige-activity-7016405649555132417-m7xj?utm_source=share&utm_medium=member_desktop

16/12/2022

Vi lanserer vår investeringskampanje i januar. Hvis du er interessert i banebrytende immunterapi for hund og menneske, registrer deg for å bli varslet når kampanjen åpner. Eller ta kontakt direkte for en tyvtitt på investeringstilbudet.
--
We are launching our fundraising campaign in January. If you are looking to support and invest in life-saving immunotherapy for dogs and humans, get notified when the campaign opens by following the link below. Or get a sneak peek at the pitch by contacting us directly.

https://lnkd.in/dsSwxtuS

Revolusjonerende kreftbehandling for hund, med direkte overføringsverdi til humanmedisin. Meget gode resultater. Kommersialisering i 23, børs i 24

12/12/2022

Vi rekrutterer nå firbeinte pasienter med lungemetastase for behandling med en av våre protokoller ved NMBU.

We are now recruiting canine patients with lung metastasis for treatment with one of our protocols at the Norwegian Life Science University.

Vi rekrutterer nå firbeinte pasienter med lungemetastase for behandling med en av våre protokoller ved NMBU. / We are now recruiting canine patients with lung…

30/11/2022

Today, to mark the end of Pet Cancer Awareness Month, we have received approval from The Norwegian Food Safety Authority (Mattilsynet) to test our Alvacan 4000 immune cell-based vaccine on privately owned dogs with cancer. The approval means that the planned phase I clinical trial can now garner data on the safety and efficacy of our vaccines, with our major goal to improve both the quality of life and life expectancy of dogs with cancer. This likely represents one of the largest studies of its kind.

Read more below....
https://lnkd.in/d3ZVpviY

Alv B receives approval for cancer study in dogs.

29/11/2022

Alv B AS files for patent protection on cancer vaccine technology.

Today, we have filed for patent protection for our innovative cancer vaccine technology. In cooperation with the patent attorney office, Potter Clarkson, we have submitted our application at the United Kingdom patent office for protection towards the development, manufacturing and sale of ALAVCAN-DC products.

The technology we are protecting can create cancer vaccines quicker and cheaper than standard DC vaccine protocols published to date, while also resulting in 50x higher cytokine secretion compared to reference protocols, during our preliminary laboratory tests.

This marks a milestone for Alv B and brings us one step closer to market and to improving cancer care in dogs and humans globally.

Read more below…
https://lnkd.in/dfh9QXiK

15/11/2022

Come and hear our Head of Clinical Development, Lars Moe, speak about how our cell therapy technology is helping improve cancer care, the challenges of creating a standardised cell therapy for canines and how they serve as an excellent model for human cancer. On Tuesday, 6th December 2022 at 15:00, we invite you to join the event at ShareLab in Forskningsparken, register below. Everyone is welcome, we hope to see you there!

Meet and network with experts in Immuno-oncology

15/11/2022

To continue all the great news, we are also very excited to announce our collaborative partnership with Oncogene AS. We will use bioinformatic technologies and expertise on biobanked genomic data from dozens of canine cancers to validate targets, develop vaccines and grow Alv B's pipeline. Oncogene is a research-based Norwegian company, using cutting edge technologies such as sequencing and bioinformatics to bring precision medicine to Norway. Together, we are committed to improving cancer care for dogs. Read more below...

https://lnkd.in/gtehCB5G

08/11/2022

We are pleased to welcome Dr Richard Crispin to the team. Richard has a Ph.D. in Pharmaceutical Chemistry from The University of Edinburgh and has a multiple years of experience working in cancer therapeutic development. He joins Alv B as a Senior Scientist developing QC and leading discovery projects. Welcome Richard!!

https://www.linkedin.com/in/richardcrispin/

08/11/2022

We are equally very excited to welcome Dr Marte Fauskanger to the Alv B team. Marte is a Molecular Biologist with a Ph.D. in Tumour Immunology from The University of Oslo. Until recently, Marte has been working at The Institute of Immunology at Oslo University Hospital on the development of CAR T cell therapies against solid tumours. Now, Marte joins us as a Senior Scientist as our R&D lead and immunology specialist. Welcome Marte!!

https://www.linkedin.com/in/marte-fauskanger-18aa9a255/

08/11/2022

We are excited to announce that Alv B AS has secured and signed exclusive licensing rights for a novel 6-target treatment with astonishing results in dogs. Through our collaboration with Diakonos Oncology, a specialist in the development of novel cancer immunotherapies, Alv B is now planning a brand new trial in Norway/EU and will continue in our goal for the improvement of cancer care in dogs. Read more below...

https://lnkd.in/dsPaASD8

27/10/2022

Don't drink the reagents!

19/09/2022

We are happy to announce that we have entered into a co-operation with AJ Vaccines A/S. AJ Vaccines is a global pharmaceutical company, that will assist with knowledge-transfer as well as vaccine components for our upcoming clinical trial.

https://alvb.no/blogg/alvb-cooperation-aj-vaccines

23/03/2022

Kampanjen har endelig åpnet, og er allerede godt i gang på folkeinvest.no. Til nå er det forhåndstegnet for over 6,8 millioner kroner fordelt på 140 investorer.

Har du ikke sett tilbudsteksten enda finner du den her: https://folkeinvest.no/kampanje/alv-b-as

Tusen takk for tilliten til alle som har forhåndstegnet, nå gleder vi oss til å få med fler på laget.

Utvikler nyskapende kreftvaksiner for hund og katt. Utprøves i klinikk allerede 2. kvartal 2022. Ekspansjon til USA og Europa mot 2023.

11/01/2022

Francesca Lockwood is a London native, with an educational background comprised of a first-class BSc in Pharmacology, an Erasmus placement, a Distinction in a Masters of Research degree in Cellular and Molecular Neuro-oncology and almost 4 years as a Research Assistant/PhD candidate in mechanistic cardiac dysfunction investigation.

Francesca has also been involved in:
- Cancer biology and chemotherapeutic resistance through REDOX adaptation research

- Cancer research exploiting the Warburg effect as a potential therapy through ketones

- Cell culture, cellular models, maintenance of biobanks of cell lines and primary cells from patient-derived glioblastoma multiforme tumors.

-Extensive molecular biology and immunohistochemistry techniques

At Alv B Francesca will be researching high grade tumors, and the use of nanoparticles in vaccines.

21/12/2021

Steven Verhaegen joined the ALV-B team as Senior Industrial Scientist in December 2021. He will use his extensive cell biology knowledge to help the team develop new therapeutic approaches and diagnostic tools for cancers in dogs and cats.

Steven gained his Licentiaat in Biological Sciences at the Free University of Brussels, Belgium in 1985. He was a European Capacity and Mobility fellow at St. Patrick’s College, Maynooth, Republic of Ireland, where he gained his PhD in 1995. He has a strong interest in cellular and molecular aspects of cancer, and has since been involved in research projects in Ireland, Brazil, and Spain. In 2007 he joined the Norges Veterinærhøgskole at Adamstuen, Oslo (presently NMBU, Ås) where he worked on cell models investigating developmental and cancer related effects of environmental pollutants. He was work package leader in PROTECTED, an EU Horizon 2020 Integrated Training Network project coordinated by Queen’s University Belfast, Northern Ireland, UK investigating endocrine disrupting effects of natural and man-made environmental toxicants. In his free time Steven likes exploring Østmarka, photography, and cooking.

06/12/2021

Francesca Gatti is an Industrial Scientist at ALV B. She is a molecular and cellular biologist with a PhD in Biotechnology with focus on immunology and biomaterials, from the University of Salento in collaboration with Harvard Medical School. Her academic research has been mostly in the areas of cell therapy, cell immuno-shielding with biomaterials, and immunotherapy for inflammatory and autoimmune diseases. She has worked in murine and non-human primate pre-clinical models, and GMP manufacturing for isolation of human cells in a clinical trial for cell therapy of type I diabetes. Francesca left academia in 2019 to be project leader in a start-up developing solutions for molecular diagnostics of infectious diseases and cancer.

From 2021, as Industrial Scientist at ALV B, Francesca uses her know-how and expertise to develop, with the rest of the team, innovative treatments and diagnostic tools for solid cancers in dogs and cats.

28/10/2021

21/09/2021

We are pleased to announce that “Innovation Norway” has offered Alv B a grant for the commercialization of Alv B’s product range within immunotherapy, and diagnostics for cats and dogs with cancer.

«Innovation Norway is the Norwegian Government’s most important instrument for innovation and development of Norwegian enterprises and industry.»

18/09/2021